Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.Melanoma Research|December 21, 2017
Quality of life patient-reported outcomes for locally advanced cutaneous melanomaEvan S Weitman, Matthew Perez, John F Thompson, et al.American Journal of Physiology. Heart and Circulatory Physiology|November 22, 2015
Impact of age on the vasodilatory function of human skeletal muscle feed arteriesSong-Young Park, Stephen J Ives, Jayson R Gifford, et al.Current Oncology Reports|June 11, 2005
Imatinib resistance in gastrointestinal stromal tumorsLei L Chen, Mahyar Sabripour, Robert H I Andtbacka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaIgor Puzanov, Mohammed M Milhem, David Minor, et al.Annals of Surgery|December 24, 2005
Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathwaysRobert H I Andtbacka, Gildy Babiera, S Eva Singletary, et al.American Journal of Physiology. Heart and Circulatory Physiology|August 31, 2014
α1- and α2-adrenergic responsiveness in human skeletal muscle feed arteries: the role of TRPV ion channels in heat-induced sympatholysisJayson R Gifford, Stephen J Ives, Song-Young Park, et al.Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.Annals of Surgical Oncology|June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialRobert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.Head & Neck|July 14, 2016
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanomaRobert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, et al.Pageof 6